Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications.
about
A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents.Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Beyond PubMed: Searching the "Grey Literature" for Clinical Trial Results.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachAripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.Drug safety evaluation of ziprasidone.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Olanzapine-fluoxetine combination for the treatment of bipolar depression.Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Quetiapine extended release for the treatment of bipolar disorder.Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Weight gain and antipsychotics: a drug safety review.Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Quantifying clinical relevance.Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to bCariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
P2860
Q30353864-0812CCA0-484C-4B5A-9A7A-8AA41E621C83Q34097289-399122B9-6F07-4ECA-BEE6-D9DB24B37F19Q34226261-C4BD25F7-4E79-472C-85E4-57873B062A47Q34252774-A1EFD38C-1F96-49D7-9E10-155929E59593Q34347796-F62CDD6E-767F-463C-9341-4CE69EC068A5Q34369664-1FFFA518-D88A-42FA-8BF1-213712FEC7AEQ34377470-905BB172-CCEC-4621-9B5D-44979D4B877DQ34464293-04E7FBB7-6755-4DD4-A17E-567C432C75C6Q34501911-CDA0862D-84AA-498D-AED5-31845463A9F5Q34626111-B6782D58-C770-46FD-B25A-EFA0C1C3CBBFQ36774139-B5AC9EEC-62C8-48FB-9C9F-511EC2CC2518Q37777006-C70E8D85-888A-4DFB-A7D0-1600BDE1AC42Q37815561-39733CF1-C734-4CC7-826B-415371D14306Q37844574-205705D4-6464-4DB9-857E-7DE9B9430D70Q37865505-37D9C46E-79B4-49A2-9A7B-598FA9BC2AC7Q37950471-F1C76929-1C4C-4B2A-8B02-ED8169D3027AQ37979497-354EA575-8F16-4090-8F63-D6B3B328D3F6Q38097886-661C4899-0016-47E8-A64B-C731476C2311Q38156001-98BE289F-C1A7-4464-8DD6-7E1E4E0F2D02Q38237319-17667055-ED1A-4B20-B94C-A0627A126F7AQ38250849-9A56CA88-F813-4933-AFEF-36D0A0686268Q38268590-FBB102CD-2AAE-4555-A051-657901A6679DQ38370764-6B6EF5E1-F28B-4557-A8AA-015C2B1E3A28Q38694855-BB90A595-81BA-4E3A-9B27-3099A4C33825Q38789841-56422043-0392-4D9A-87B3-ECE018FCDD10Q41769033-F940D04E-FE2D-48D7-8456-22791A50F0CCQ44797813-E227298B-847B-47ED-AF2A-520F3D081D9DQ47675010-BFD6A305-B4BA-46AD-AED7-1678586D7CECQ56790616-F450A23D-FA1D-41F7-B4D8-DBEA2AB068BAQ57483192-8C980B54-A58C-43B1-8402-DA87F14154CC
P2860
Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Quantifying risk: the role of ...... of antipsychotic medications.
@en
Quantifying risk: the role of ...... of antipsychotic medications.
@nl
type
label
Quantifying risk: the role of ...... of antipsychotic medications.
@en
Quantifying risk: the role of ...... of antipsychotic medications.
@nl
prefLabel
Quantifying risk: the role of ...... of antipsychotic medications.
@en
Quantifying risk: the role of ...... of antipsychotic medications.
@nl
P1433
P1476
Quantifying risk: the role of ...... of antipsychotic medications.
@en
P304
P356
10.2174/157488609789006985
P577
2009-09-01T00:00:00Z